Komori
ReproCELL (4978) · InitiativeAdvanced

Incentives for Directors and Employees to Enhance Corporate Value Through Restricted Stock Compensation

First written in FY2019-Q1. 6 of 9 entries say "Advanced", first in FY2020-Q2. Latest entry: FY2026.

9entries
9years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseAdvancedFY2019-Q2 – FY20262018: 220182019: 120192020: 120202021: 120212022: 020222023: 120232024: 120242025: 120252026: 12026
Same theme, other companies
Grant and Issuance of Equity Compensation to Employees and Officers (Stock Options and Restricted Stock)A theme 658 companies write about · 0 as a headwind · 739 as a tailwind
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 179 companies compared. The sentences above are computed from all 179.Comparing 200 of the theme's 741 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「18 March 2026 (Note) 2 345,000」

    The company issued 345,000 shares on 18 March 2026 as restricted stock compensation, implementing an additional incentive measure to align the interests of officers and employees with shareholders and enhance corporate value over the medium to long term.
  2. FY2025AdvancedAnnual report

    「Increase from the issuance of new shares as restricted stock compensation 471,000 shares」

    The company issued 471,000 shares as restricted stock compensation, implementing an additional incentive measure to align the interests of officers and employees with shareholders and enhance corporate value over the medium to long term.
  3. FY2024-Q3AdvancedAnnual report

    「On 26 January 2024, the company decided to allot 325,000 common shares as specified restricted stock.」

    The company issued 325,000 shares as restricted stock compensation to directors, employees and others in Japan and overseas, implementing an additional incentive measure to align the interests of officers and employees with shareholders and enhance corporate value.
  4. FY2023AdvancedAnnual report

    「24 March 2023 (Note) 2 187,000」

    The company issued 187,000 shares on 24 March 2023 as restricted stock compensation, implementing an additional incentive measure to align the interests of officers and employees with shareholders and enhance corporate value over the medium to long term.
  5. FY2021AdvancedAnnual report

    「5 March 2021」

    The company issued 155,500 shares on 5 March 2021 as restricted stock compensation, implementing an additional incentive measure to align the interests of officers and employees with shareholders and enhance corporate value.
  6. FY2020-Q3AchievedAnnual report

    「31 October 2019 (Note) 2 185,500」

    For the restricted stock compensation decided in the previous filing, the company issued 185,500 new shares on 31 October 2019 and completed the share allocation.
  7. FY2020-Q2AdvancedAnnual report

    「At a meeting of the Board of Directors held on 3 October 2019, the company decided, based on a resolution of the Board of Directors and a decision by the company's Representative Director and President, to provide total monetary compensation claims of ¥43,778,000 to 2 company directors excluding outside directors, 4 company employees, 4 directors of subsidiaries and 6 subsidiary employees, collectively referred to as the allotment recipients, for restricted stock compensation covering the period from the company's 17th Annual General Meeting of Shareholders through the 19th Annual General Meeting of Shareholders scheduled for June 2021. The company will allot 185,500 common shares as specified restricted stock, with the allotment recipients contributing the full amount of the monetary compensation claims in kind.」

    At its October 2019 Board of Directors meeting, the company decided to allot 185,500 restricted shares as compensation to 16 directors and employees in Japan and overseas, implementing an additional allocation under the existing scheme.
  8. FY2019-Q2AchievedAnnual report

    「The increase resulted from the issuance of new shares as restricted stock compensation.」

    The company issued 153,500 new shares on 14 August 2018 as restricted stock compensation and carried out the share allocation under the scheme.
  9. FY2019-Q1First statedAnnual report

    「The company decided to allot 153,500 common shares as specified restricted stock. The restriction period is set at 2 years in order to achieve over the medium term the purpose of introducing the plan: to share the benefits and risks of share-price movements with shareholders and further increase officers' and employees' motivation to contribute to share-price appreciation and enhanced corporate value.」

    The company is implementing a scheme that allocates 153,500 restricted shares to directors and employees, including those of overseas subsidiaries, to align their interests with shareholders and increase their motivation to contribute to enhanced corporate value.
Moved together

"Raising Funds for Cell Therapy Product Development and Clinical Trials through the 12th Series of Stock Acquisition Rights" moved the same way as this thread, in the same document, in 7 of its 9 moves.

754444★123456
  1. ★This thread
  2. 1Raising Funds for Cell Therapy Product Development and Clinical Trials through the 12th Series of Stock Acquisition Rights7×
  3. 2Exclusive development and marketing of Stemchymal® in Japan5×
  4. 3Differentiation through a broad lineup of research reagents, cell products and contract services4×
  5. 4Risk of delayed elimination of accumulated deficits4×
  6. 5Research Support Business Segment Turning Profitable4×
  7. 6Global expansion leveraging sales channels in Japan, the US and Europe4×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for ReproCELL yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.